Přejít k obsahu
Merck
  • Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors.

Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors.

ChemMedChem (2011-04-21)
Roberta Ettari, Cinzia Bonaccorso, Nicola Micale, Cornelia Heindl, Tanja Schirmeister, Maria Luisa Calabrò, Silvana Grasso, Maria Zappalà
ANOTACE

Proteasome inhibition is a topic of great interest in anticancer research. The proteolytic activity of this multicatalytic complex relies on three subunits, β1, β2 and β5, containing a caspase-like, a trypsin-like and a chymotrypsin-like active site, respectively. Several studies have demonstrated that, of the three activities, the chymotrypsin-like activity was the most necessary for cell viability and protein processing. Thus, most efforts towards the development of proteasome inhibitors have focused on the selective inhibition of the β5 subunit active site. Herein, we report the design and synthesis of a series of conformationally constrained tripeptidyl vinyl sulfones were determined to be good inhibitors of the chymotrypsin-like activity of proteasome, with K(I) values in the sub-micromolar to micromolar range. These compounds were also tested against bovine pancreatic α-chymotrypsin and human cathepsin B and L, revealing a good selectivity for the target enzyme over these related enzymes.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Sigma-Aldrich
Divinyl sulfone, contains hydroquinone as inhibitor, ≥96%
Sigma-Aldrich
α-Chymotrypsin from bovine pancreas, ≥40 units/mg protein, vial of 5 mg